Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Shanghai YingLi Pharmaceutical Co. Ltd. clinical trials
The registry lists 24 studies whose lead sponsor is Shanghai YingLi Pharmaceutical Co. Ltd.. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 9, 2025.
Keep track of what changes. Save the Shanghai YingLi Pharmaceutical Co. Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shanghai YingLi Pharmaceutical Co. Ltd..
- Shanghai YingLi Pharmaceutical Co. Ltd.24 studiesSame company
Something wrong?
Focus areas
Conditions Shanghai YingLi Pharmaceutical Co. Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRASRecruitingNCT06096974Phase 1
- A Study of AK-1286 in Patients With Advanced Solid TumorsNot yet recruitingNCT06779045Phase 1
- YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic CancerNot yet recruitingNCT06662669Phase 1/2
- A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell LymphomaNot yet recruitingNCT06548347Phase 2/3
- A National Multicenter, Real-world Study of Linperlisib in the Treatment of LymphomaNot yet recruitingNCT06343935Phase 4
- A Study of YL-17231 in Patients With Advanced Solid TumorsRecruitingNCT06078800Phase 1
- A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid TumorNot yet recruitingNCT06026501Phase 1/2
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
- A Study of HY-0102 in Patients With Advanced Solid TumorsStatus unknownNCT06094777Phase 1
- Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS MutationStatus unknownNCT05173805Phase 1/2
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT05274997Phase 2
- A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid TumorsStatus unknownNCT05457517Phase 1/2
- A Study of Linperlisib Combination With Camrelizumab in Patients With Solid TumorStatus unknownNCT05429398Phase 1
- YL-13027 in Patients With Advanced Solid TumorsStatus unknownNCT05228600Phase 1
- First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid TumorsStatus unknownNCT03869632Phase 1
- A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C MutationStatus unknownNCT05119933Phase 1/2
- A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic CancerStatus unknownNCT04975061
- A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownNCT04108325Phase 1
- A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT04705090Phase 2
- YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownNCT04500561Phase 1/2
- A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's LymphomaStatus unknownNCT04370405Phase 2
- A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular LymphomaStatus unknownNCT04379167Phase 2
- A Phase I Study of YY-20394 in Patients With Advanced Solid TumorsStatus unknownNCT04049929Phase 1
- A Phase I Study of YY-20394 in Patients With B Cell Hematologic MalignanciesStatus unknownNCT03757000Phase 1